Simon Read Biography and Net Worth

Director of Dianthus Therapeutics

Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experience.

Dr. Read most recently served as CEO and founder of Mariana Oncology until its acquisition by Novartis and was Chief Scientific Officer at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma. Prior to this, he held R&D leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech and worked on the clinical development of some of the most well-known drugs in the immunology area, including Rituxan® and Actemra®. Dr. Read is a Fellow of the Royal Society of Medicine (UK) and Chairman of the Board of Ethyreal Bio. He previously served on the Board of Triana Biomedicines and Oxstem Ltd (UK). He obtained his Ph.D. from University of Hertfordshire, studied Physiology at the University of Manchester in the UK, and has authored over 50 articles in peer reviewed journals.

What is Simon Read's net worth?: The estimated net worth of Simon Read is at least $301.28 thousand as of August 10th, 2026. Dr. Read owns 2,777 shares of Dianthus Therapeutics stock worth more than $301,277 as of August 12th. This net worth evaluation does not reflect any other investments that Dr. Read may own. Learn More about Simon Read's net worth.
How do I contact Simon Read?: The corporate mailing address for Dr. Read and other Dianthus Therapeutics executives is 203 Crescent Street, Building 17 Suite 102B, Waltham, MA 02453, United States, . Dianthus Therapeutics can also be reached via phone at 857-242-0170 and via email at [email protected]. Learn More on Simon Read's contact information.
Has Simon Read been buying or selling shares of Dianthus Therapeutics?: During the past quarter, Simon Read has sold $304,220.35 of Dianthus Therapeutics stock. Most recently, Simon Read sold 2,777 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.55, for a transaction totalling $304,220.35. Following the completion of the sale, the director now directly owns 2,777 shares of the company's stock, valued at $304,220.35. Learn More on Simon Read's trading history.
Who are Dianthus Therapeutics' active insiders?: Dianthus Therapeutics' insider roster includes Edward Carr (Chief Accounting Officer), Marino Garcia (President & Chief Executive Officer, Board Member), Anne McGeorge (Director), Simrat Randhawa (Insider), Simon Read (Director), Ryan Savitz (CFO), and Adam Veness (SVP). Learn More on Dianthus Therapeutics' active insiders.
Are insiders buying or selling shares of Dianthus Therapeutics?: During the last twelve months, insiders at the sold shares 17 times. They sold a total of 843,865 shares worth more than $64,836,552.05. The most recent insider tranaction occured on August, 10th when Director Anne Mcgeorge sold 7,750 shares worth more than $844,827.50. Insiders at Dianthus Therapeutics own 3.0% of the company. Learn More about insider trades at Dianthus Therapeutics.
Information on this page was last updated on 8/10/2026.

Simon Read Insider Trading History at Dianthus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2026	Sell	2,777	$109.55	$304,220.35	2,777

Simon Read Buying and Selling Activity at Dianthus Therapeutics

Dianthus Therapeutics Company Overview

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Today's Range

Now: $109.49

$108.36

$110.22

50 Day Range

MA: $95.71

$76.42

$112.64

2 Week Range

Now: $109.49

$19.75

$114.55

Volume

46,939 shs

Average Volume

966,317 shs

Market Capitalization

$5.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22